Lives unaffected by cystic fibrosis


Back to the Drug Development Pipeline

Inhaled Nitric Oxide (LungFit™ GO)

Phase Two

Phase Two

Therapeutic Approach


LungFit™ GO is a portable inhaled nitric oxide treatment that is being tested for treatment of nontuberculous mycobacteria (NTM), a difficult-to-treat bacteria that infects the lungs of people with CF. Nitric oxide is a gas molecule produced by the body that plays a key role in the immune system. Nitric oxide has been shown to kill bacteria and break down their biofilms -- protective layers formed by bacteria that make them more difficult to eliminate. Researchers believe that increasing levels of nitric oxide in the body could help eliminate bacteria and increase lung function in people with CF. 


A pilot study to evaluate the safety and effectiveness of LungFit™ GO is currently underway in Australia.


This program is sponsored by Beyond Air and is partially funded by the Cystic Fibrosis Foundation.

Contact us about Inhaled Nitric Oxide (LungFit™ GO) >